Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia.
作者： M. Florentin , E. N. Liberopoulos , D. P. Mikhailidis , M. S. Elisaf
关键词:
摘要: ABSTRACTObjective: Hypercholesterolaemia is a major risk factor for atherosclerosis and coronary heart disease. Treatment with lipid lowering agents reduces the of vascular events. Colesevelam novel bile acid sequestrant (BAS) indicated treatment hypercholesterolaemia, either as monotherapy or in combination statins.Scope: This article reviews efficacy, tolerability safety colesevelam clinical practice. The literature search was based on PubMed up to January 2008.Findings: Colesevelam, used alone other hypolipidaemic (statins, ezetimibe fenofibrate), has an overall favourable effect profile. Specifically, total low-density lipoprotein cholesterol (LDL-C) apolipoprotein B levels increases high-density AI. However, may slightly raise triglyceride levels. can improve glycaemic control diabetic patients. Moreover, it m...
informahealthcare.com参考文章(72)
Ira D. Galin, Donald A. Smith, Letter to the Editor American Heart Journal. ,vol. 151, pp. e1- ,(2006) , 10.1016/J.AHJ.2005.10.009
D. B. Hunninghake, M. E. Stepanavage, M. R. Melino, C. A. Dujovne, H. G. Schrott, E. A. Stein, D. Kush, W. Insull, S. Campodónico, I. D. Escobar, R. S. Scott, A. C. Tate, M. Wu, M. Mercuri, Y. B. Mitchel, S. R. Weiss, M. Bertolami, L. Ose, H. Bays, J. J P Kastelein, M. H. Davidson, Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. Nutrition Metabolism and Cardiovascular Diseases. ,vol. 10, pp. 253- 262 ,(2000)
William Insull, Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. Southern Medical Journal. ,vol. 99, pp. 257- 273 ,(2006) , 10.1097/01.SMJ.0000208120.73327.DB
Joanne M. Donovan, Daria Stypinski, Mark R. Stiles, Timothy A. Olson, Steven K. Burke, Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovascular Drugs and Therapy. ,vol. 14, pp. 681- 690 ,(2000) , 10.1023/A:1007831418308
Laurence S. Sperling, Benjamin D. Mackie, Sameer Satija, Christine Nell, Joseph Miller, Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy. American Journal of Cardiology. ,vol. 99, pp. 291- ,(2007) , 10.1016/J.AMJCARD.2006.07.093
Carole Brendel, Kristina Schoonjans, Oronza A. Botrugno, Eckardt Treuter, Johan Auwerx, The Small Heterodimer Partner Interacts with the Liver X Receptor α and Represses Its Transcriptional Activity Molecular Endocrinology. ,vol. 16, pp. 2065- 2076 ,(2002) , 10.1210/ME.2001-0194
Shannon Rivers, Michael Kane, Robert Busch, Gary Bakst, Robert Hamilton, Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Endocrine Practice. ,vol. 13, pp. 11- 16 ,(2007) , 10.4158/EP.13.1.11
Mitsuhiro Watanabe, Sander M. Houten, Li Wang, Antonio Moschetta, David J. Mangelsdorf, Richard A. Heyman, David D. Moore, Johan Auwerx, Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. Journal of Clinical Investigation. ,vol. 113, pp. 1408- 1418 ,(2004) , 10.1172/JCI21025
Marc Evans, Alan Rees, Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Safety. ,vol. 25, pp. 649- 663 ,(2002) , 10.2165/00002018-200225090-00004
Michael J Zema, Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. American Journal of Therapeutics. ,vol. 12, pp. 306- 310 ,(2005) , 10.1097/01.MJT.0000155109.69831.A3